Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.31 |
| ▸ | FNTA | P49354 | 2/20 | 0.30 |
| ▸ | FNTB | P49356 | 2/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277342 | 0.99 | KMT2A (0.36) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL3278899 | 0.97 | KMT2A (0.35) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL3337614 | 0.97 | KMT2A (0.35) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| Potassium Ion SCHEMBL19951026 | 0.84 | FAAH (0.34) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL19950982 | 0.84 | FAAH (0.34) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL2582839 | 0.82 | KMT2A (0.53) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL3341655 | 0.80 | FNTA (0.34) | FNTAFNTB | |
| SCHEMBL2576072 | 0.80 | KMT2A (0.51) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL4622252 | 0.79 | KMT2A (0.44) | KMT2AFAAHMEN1MAPK1PLA2G10 | |
| SCHEMBL4419239 | 0.79 | KMT2A (0.44) | KMT2AFAAHMEN1MAPK1PLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | SENJU PHARMACEUTICAL CO. LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7700080-B2 | Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| US-20040092586-A1 | Novel a-lipoic acid derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1371640-A1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | TYR, SERPINB1, LPO | KMT2A 2439/4885FAAH 1636/4885MEN1 1715/4885 |
| US-20040092586-A1 | Novel a-lipoic acid derivative and use thereof | TYR, SERPINB1, LPO | KMT2A 2257/4885FAAH 1603/4885MEN1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.